Medivation to take 2-for-1 split of soaring stock Sept. 21

Medivation CEO David Hung.

Medivation Inc., whose stock has soared more than 500 percent since early November, will take a 2-for-1 split of its common stock, the company said Tuesday. Due to the promise of its late-stage experimental prostate cancer drug enzalutamide, the San Francisco-based drug developer (NASDAQ: MDVN) has seen its stock rise to a 52-week high of $103.89, from $16.10 per share less than 10 months ago.